Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2005

Open Access 01-03-2005 | Research article

Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis

Authors: Patrick H Dessein, Barry I Joffe, Sham Singh

Published in: Arthritis Research & Therapy | Issue 3/2005

Login to get access

Abstract

Cardiovascular event rates are markedly increased in rheumatoid arthritis (RA), and RA atherogenesis remains poorly understood. The relative contributions of traditional and nontraditional risk factors to cardiovascular disease in RA await elucidation. The present study comprises three components. First, we compared biomarkers of endothelial dysfunction (vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1 and endothelial leucocyte adhesion molecule [ELAM]-1) in 74 RA patients and 80 healthy control individuals before and after controlling for traditional and nontraditional cardiovascular risk factors, including high-sensitivity C-reactive protein (hs-CRP), IL-1, IL-6 and tumor necrosis factor-α. Second, we investigated the potential role of an extensive range of patient characteristics in endothelial dysfunction in the 74 RA patients. Finally, we assessed associations between biomarkers of endothelial dysfunction and ultrasonographically determined common carotid artery intima–media thickness and plaque in RA. The three biomarkers of endothelial dysfunction, as well as hs-CRP, IL-1, IL-6 and tumor necrosis factor-α, were higher in patients than in control individuals (P < 0.0001). Patients were also older, exercised less and had a greater waist circumference, blood pressure and triglyceride levels (P ≤ 0.04). Five patients had diabetes. Differences in endothelial function were no longer significant between patients and controls (P = 0.08) only after both traditional and nontraditional cardiovascular risk factors were controlled for. In the 74 RA patients, IL-6 predicted levels of all three biomarkers (P ≤ 0.03), and rheumatoid factor titres and low glomerular filtration rate (GFR) both predicted levels of VCAM-1 and ICAM-1, independent of traditional cardiovascular risk factors (P ≤ 0.02). VCAM-1 was associated with common carotid artery intima–media thickness (P = 0.02) and plaque (P = 0.04) in RA. Patients had impaired endothelial function, less favourable traditional cardiovascular risk factor profiles, and higher circulating concentrations of hs-CRP and cytokines compared with healthy control individuals. Both traditional and nontraditional cardiovascular risk factors contributed to the differences in endothelial function between RA patients and healthy control individuals. IL-6, rheumatoid factor titres and low GFR were independently predictive of endothelial dysfunction in RA. Disease-modifying agents that effectively suppress both cytokine and rheumatoid factor production, and interventions aimed at preserving renal function may attenuate cardiovascular risk in RA.
Literature
1.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307. 10.1161/01.CIR.0000054612.26458.B2.CrossRefPubMed Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307. 10.1161/01.CIR.0000054612.26458.B2.CrossRefPubMed
2.
go back to reference Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003, 30: 36-40.PubMed Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003, 30: 36-40.PubMed
3.
go back to reference del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44: 2737-2745. 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#.CrossRefPubMed del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44: 2737-2745. 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#.CrossRefPubMed
4.
go back to reference Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003, 108: 2957-2963. 10.1161/01.CIR.0000099844.31524.05.CrossRefPubMed Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003, 108: 2957-2963. 10.1161/01.CIR.0000099844.31524.05.CrossRefPubMed
5.
go back to reference Dessein PH, Joffe BI, Stanwix AE: Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol. 2003, 30: 1403-1405.PubMed Dessein PH, Joffe BI, Stanwix AE: Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol. 2003, 30: 1403-1405.PubMed
6.
go back to reference Wallberg-Jonsson S, Ohman ML, Dahlqvist SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997, 24: 445-451.PubMed Wallberg-Jonsson S, Ohman ML, Dahlqvist SR: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997, 24: 445-451.PubMed
7.
go back to reference Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002, 46: 1489-1497. 10.1002/art.10269.CrossRefPubMed Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E, Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002, 46: 1489-1497. 10.1002/art.10269.CrossRefPubMed
8.
go back to reference Nagata-Sakurai M, Inaba M, Goto H, Kumeda y, Furumitsu Y, Inui K, Koyama H, Emoto M, Ishimura E, Shoji T, Nishizawa Y: Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 3061-3067. 10.1002/art.11327.CrossRefPubMed Nagata-Sakurai M, Inaba M, Goto H, Kumeda y, Furumitsu Y, Inui K, Koyama H, Emoto M, Ishimura E, Shoji T, Nishizawa Y: Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 3061-3067. 10.1002/art.11327.CrossRefPubMed
9.
go back to reference Belcaro G, Nicolaides AN, Ramaswami G, Cesarone MR, De Sanctis M, Incandela L, Ferrari P, Geroulakos G, Barsotti A, Griffin M, et al: Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVES study (1)). Atherosclerosis. 2001, 156: 379-387. 10.1016/S0021-9150(00)00665-1.CrossRefPubMed Belcaro G, Nicolaides AN, Ramaswami G, Cesarone MR, De Sanctis M, Incandela L, Ferrari P, Geroulakos G, Barsotti A, Griffin M, et al: Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVES study (1)). Atherosclerosis. 2001, 156: 379-387. 10.1016/S0021-9150(00)00665-1.CrossRefPubMed
10.
go back to reference Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003, 23: 168-175. 10.1161/01.ATV.0000051384.43104.FC.CrossRefPubMed Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003, 23: 168-175. 10.1161/01.ATV.0000051384.43104.FC.CrossRefPubMed
11.
go back to reference Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, Hajeer AH, Ollier WE, Mattey DL, Gonzalez-Gay MA: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003, 114: 647-652. 10.1016/S0002-9343(03)00133-5.CrossRefPubMed Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Vidan J, Hajeer AH, Ollier WE, Mattey DL, Gonzalez-Gay MA: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003, 114: 647-652. 10.1016/S0002-9343(03)00133-5.CrossRefPubMed
12.
go back to reference Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004, 63: 31-35. 10.1136/ard.2003.007740.PubMedCentralCrossRefPubMed Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004, 63: 31-35. 10.1136/ard.2003.007740.PubMedCentralCrossRefPubMed
13.
go back to reference Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, et al: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002, 106: 2184-2187. 10.1161/01.CIR.0000037521.71373.44.CrossRefPubMed Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, et al: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002, 106: 2184-2187. 10.1161/01.CIR.0000037521.71373.44.CrossRefPubMed
14.
go back to reference Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2002, 22: 1637-1641. 10.1161/01.ATV.0000033516.73864.4E.CrossRefPubMed Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2002, 22: 1637-1641. 10.1161/01.ATV.0000033516.73864.4E.CrossRefPubMed
15.
go back to reference Van Doornum S, McColl G, Jenkins A: Screening for atherosclerosis in patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 72-80. 10.1002/art.10735.CrossRefPubMed Van Doornum S, McColl G, Jenkins A: Screening for atherosclerosis in patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 72-80. 10.1002/art.10735.CrossRefPubMed
16.
go back to reference Meigs JB, Hu FB, Rifai N, Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004, 291: 1978-1986. 10.1001/jama.291.16.1978.CrossRefPubMed Meigs JB, Hu FB, Rifai N, Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004, 291: 1978-1986. 10.1001/jama.291.16.1978.CrossRefPubMed
17.
go back to reference Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S: Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis. 2004, 172: 299-308. 10.1016/j.atherosclerosis.2003.11.003.CrossRefPubMed Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S: Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis. 2004, 172: 299-308. 10.1016/j.atherosclerosis.2003.11.003.CrossRefPubMed
18.
go back to reference Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation. 1997, 96: 4219-4225.CrossRefPubMed Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation. 1997, 96: 4219-4225.CrossRefPubMed
19.
go back to reference De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M, Carmassi F, Pedrinelli R: Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997, 17: 2646-2654.CrossRefPubMed De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M, Carmassi F, Pedrinelli R: Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997, 17: 2646-2654.CrossRefPubMed
20.
go back to reference O'Malley T, Ludlam CA, Riemermsa RA, Fox KA: Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1): potential risk factor for the acute coronary syndromes. Eur Heart J. 2001, 22: 1226-1234. 10.1053/euhj.2000.2480.CrossRefPubMed O'Malley T, Ludlam CA, Riemermsa RA, Fox KA: Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1): potential risk factor for the acute coronary syndromes. Eur Heart J. 2001, 22: 1226-1234. 10.1053/euhj.2000.2480.CrossRefPubMed
21.
go back to reference Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D: Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001, 358: 971-976. 10.1016/S0140-6736(01)06104-9.CrossRefPubMed Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D: Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001, 358: 971-976. 10.1016/S0140-6736(01)06104-9.CrossRefPubMed
22.
go back to reference Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3444-3449. 10.1002/art.20636.CrossRefPubMed Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3444-3449. 10.1002/art.20636.CrossRefPubMed
23.
go back to reference Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002, 29: 875-882.PubMed Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvist S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002, 29: 875-882.PubMed
24.
go back to reference Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE: Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1098-1102.CrossRefPubMed Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE: Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1098-1102.CrossRefPubMed
25.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.CrossRefPubMed
26.
go back to reference Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, Stanwix AE: Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005, 32: 435-442.PubMed Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K, Stanwix AE: Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005, 32: 435-442.PubMed
27.
go back to reference Dessein PH, Joffe BI, Stanwix AE: Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid. 2004, 14: 443-446. 10.1089/105072504323150750.CrossRefPubMed Dessein PH, Joffe BI, Stanwix AE: Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid. 2004, 14: 443-446. 10.1089/105072504323150750.CrossRefPubMed
28.
go back to reference Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ: Soluble cell adhesion molecules-P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol. 1998, 27: 296-299. 10.1080/030097498442415.CrossRefPubMed Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ: Soluble cell adhesion molecules-P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol. 1998, 27: 296-299. 10.1080/030097498442415.CrossRefPubMed
29.
go back to reference El M, Ashour S, Moustafa H, Ahmed I: Altered levels of soluble adhesion molecules in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol. 2002, 29: 57-61.PubMed El M, Ashour S, Moustafa H, Ahmed I: Altered levels of soluble adhesion molecules in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol. 2002, 29: 57-61.PubMed
30.
go back to reference Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002, 4: R5-10.1186/ar428.PubMedCentralCrossRefPubMed Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002, 4: R5-10.1186/ar428.PubMedCentralCrossRefPubMed
31.
go back to reference Van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis?. Arthritis Rheum. 2002, 46: 862-783. 10.1002/art.10089.CrossRefPubMed Van Doornum S, McColl G, Wicks IP: Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis?. Arthritis Rheum. 2002, 46: 862-783. 10.1002/art.10089.CrossRefPubMed
32.
go back to reference Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997, 24: 1477-1485.PubMed Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997, 24: 1477-1485.PubMed
33.
go back to reference Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.CrossRefPubMed Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.CrossRefPubMed
34.
go back to reference Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998, 128: 127-137.CrossRefPubMed Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998, 128: 127-137.CrossRefPubMed
35.
go back to reference Duff GW: Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl. 1994, 100: 9-19.CrossRefPubMed Duff GW: Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl. 1994, 100: 9-19.CrossRefPubMed
36.
go back to reference Ou LS, See LC, Wu CJ, Kao CC, Lin YL, Huang JL: Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol. 2002, 21: 52-56. 10.1007/s100670200012.CrossRefPubMed Ou LS, See LC, Wu CJ, Kao CC, Lin YL, Huang JL: Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol. 2002, 21: 52-56. 10.1007/s100670200012.CrossRefPubMed
37.
go back to reference Maini RN, Feldman M: How does infliximab work in rheumatoid arthritis?. Arthritis Res. 2002, 22-28. 10.1186/ar549. Maini RN, Feldman M: How does infliximab work in rheumatoid arthritis?. Arthritis Res. 2002, 22-28. 10.1186/ar549.
38.
go back to reference Barrera P, Boerbooms AM, Demacker PN, van de Putte LB, Gallati H, van der Meer JW: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol. 1994, 33: 1017-1024.CrossRefPubMed Barrera P, Boerbooms AM, Demacker PN, van de Putte LB, Gallati H, van der Meer JW: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol. 1994, 33: 1017-1024.CrossRefPubMed
39.
go back to reference Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P: C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens. 2003, 21: 1787-1803. 10.1097/00004872-200310000-00002.CrossRefPubMed Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P: C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?. J Hypertens. 2003, 21: 1787-1803. 10.1097/00004872-200310000-00002.CrossRefPubMed
40.
go back to reference George J, Afek A, Gilburd B, Shoenfeld Y, Harats D: Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol. 2001, 38: 900-905. 10.1016/S0735-1097(01)01440-1.CrossRefPubMed George J, Afek A, Gilburd B, Shoenfeld Y, Harats D: Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am Coll Cardiol. 2001, 38: 900-905. 10.1016/S0735-1097(01)01440-1.CrossRefPubMed
41.
go back to reference Newkirk MM: Rheumatoid factors: what do they tell us?. J Rheumatol. 2002, 29: 2034-2040.PubMed Newkirk MM: Rheumatoid factors: what do they tell us?. J Rheumatol. 2002, 29: 2034-2040.PubMed
42.
go back to reference Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM: T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001, 167: 4710-4718.CrossRefPubMed Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM: T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001, 167: 4710-4718.CrossRefPubMed
43.
go back to reference Edwards JC, Szczepariski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350: 2572-2581. 10.1056/NEJMoa032534.CrossRefPubMed Edwards JC, Szczepariski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350: 2572-2581. 10.1056/NEJMoa032534.CrossRefPubMed
44.
go back to reference Aubry MC, Riehle DL, Edwards WD, Maradit-Kremers H, Roger VL, Sebo TJ, Gabriel SE: B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc Pathol. 2004, 13: 233-236. 10.1016/j.carpath.2004.02.005.CrossRefPubMed Aubry MC, Riehle DL, Edwards WD, Maradit-Kremers H, Roger VL, Sebo TJ, Gabriel SE: B-lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc Pathol. 2004, 13: 233-236. 10.1016/j.carpath.2004.02.005.CrossRefPubMed
45.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, et al: American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003, 108: 2154-2169. 10.1161/01.CIR.0000095676.90936.80.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, et al: American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003, 108: 2154-2169. 10.1161/01.CIR.0000095676.90936.80.CrossRefPubMed
Metadata
Title
Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis
Authors
Patrick H Dessein
Barry I Joffe
Sham Singh
Publication date
01-03-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1717

Other articles of this Issue 3/2005

Arthritis Research & Therapy 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.